TY - THES A1 - Kung, Margret T1 - Diagnostische und prognostische Wertigkeit der kontrastmittelverstärkten Dobutamin-Stressechokardiographie bei herztransplantierten Patienten T1 - Prognostic and diagnostic value of contrast enhanced dobutamine-stressechocardiography in heart transplant recipients N2 - Für Patienten im terminalen Stadium der Herzinsuffizienz bleibt häufig als letzte Alternative die orthotope Herztransplantation. Weltweit wurden bis heute 63.000 Herztransplantationen durchgeführt. Postoperativ sind lebenslang engmaschige Kontrolluntersuchungen notwendig, um typische Komplikationen wie Transplantatvaskulopathie, akute Transplantatabstoßung, Myokardfibrose und andere Begleiterkrankungen frühzeitig diagnostizieren und therapieren zu können. Trotz der Notwendigkeit regelmäßiger Überwachung bedeutet die Herztransplantation für viele Patienten eine deutliche Verbesserung ihrer Lebensqualität. Die Komponenten der Nachsorge von herztransplantierten Patienten sind komplex, so dass diese vorwiegend an spezialisierten Einrichtungen erfolgt.7 Aufgrund der verbesserten immunsuppressiven Therapie und der dadurch bedingten längeren Überlebenszeiten nach Herztransplantation gewinnt die Transplantatvaskulopathie in der Langzeitprognose immer mehr an Bedeutung. Die Echokardiographie in Ruhe und unter Belastung ist die wichtigste nicht-invasive Methode, um mit der Transplantatvaskulopathie einhergehende Wandbewegungsstörungen rasch und kostengünstig zu diagnostizieren. Voraussetzung für eine aussagekräftige Beurteilung von Wandbewegungsstörungen ist die gute Abgrenzbarkeit von Cavum und Endokard. Die Verwendung von lungengängigen Kontrastmitteln erlaubt eine bessere ventrikuläre Kontrastierung und Endokarddelineation. Durch vergleichende Untersuchungen der eigenen Arbeitsgruppe zwischen nativen Dobutamin- Stressechokardiographien (DSE) mit intravaskulärem Ultraschall und der Koronarangiographie wurde die DSE als sensitive Methode zur Detektion der Transplantatvaskulopathie etabliert. Es ist jedoch ungeklärt, ob eine bessere Kontrastierung des Cavums nach Kontrastmittelapplikation eine präzisere Detektion von Wandbewegungsstörungen bei herztransplantierten Patienten und damit eine zuverlässigere Aussage zur Langzeitprognose erlaubt. Akosah et al. konnten bereits zeigen, dass der nativen Dobutamin-Stressechokardiographie eine prognostische Aussagekraft bezüglich kardialer Ereignisse zukommt. Zur prognostischen Aussagekraftder kontrastmittelverstärkten Dobutamin-Stressechokardiographie liegen bislang keine veröffentlichten Daten vor. Ebenso ist unklar, ob und welche im klinischen Alltag routinemäßig erhobenen Patientencharakteristika und Verlaufsparameter zur Prognoseabschätzung beitragen. Die vorliegende Arbeit untersucht an einem konsekutiv rekrutierten Kollektiv herztransplantierter Patienten die diagnostische und prognostische Wertigkeit der kontrastmittelverstärkten Dobutamin-Stressechokardiographie. N2 - For many patients with terminal heart failure heart transplantation is the ultimate therapeutical option. In order to detect complications like transplant vasculopathy, opportunistic infectious diseases, acute rejection or myocardial fibrosis careful monitoring of these patients is neccessary. Long-time prognosis has improved steadily due to better immunosuppressive treatment. An important complication for long-time survivors is transplant vasculopathy. Echocardiography is established as the most sensitive non-invasive method to detect wall motion abnormalities that are caused by transplant vasculopathy. High image quality is absolutely neccessary for propre wall motion analysis. Contrast agents allow good discriminitation of the endocardial border. It is not known yet whether contrast agent enhancement also leads to a better prognostic value. It has already been shown that native dobutamine-stressechocardiography can predict cardiovascular events. This has not been analysed for contrast enhanced stress-tests. We analysed the prognostic and diagnostic value of contrast enhanced dobutamine-stressechocardiography in 83 consecutive patients after orthotopic heart transplantation. KW - Dobutamin-Stressechokardiographie KW - Herztransplantation KW - Prognostische Aussagekraft KW - dobutamine-stressechocardiography KW - heart transplantation KW - prognostic value Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-10133 ER - TY - JOUR A1 - Schwitter, Juerg A1 - Wacker, Christian M. A1 - Wilke, Norbert A1 - Al-Saadi, Nidal A1 - Sauer, Ekkehart A1 - Huettle, Kalman A1 - Schönberg, Stefan O. A1 - Debl, Kurt A1 - Strohm, Oliver A1 - Ahlstrom, Hakan A1 - Dill, Thorsten A1 - Hoebel, Nadja A1 - Simor, Tamas T1 - Superior diagnostic performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: The secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial) JF - Journal of Cardiovascular Magnetic Resonance N2 - Background: Perfusion-cardiovascular magnetic resonance (CMR) is generally accepted as an alternative to SPECT to assess myocardial ischemia non-invasively. However its performance vs gated-SPECT and in sub-populations is not fully established. The goal was to compare in a multicenter setting the diagnostic performance of perfusion-CMR and gated-SPECT for the detection of CAD in various populations using conventional x-ray coronary angiography (CXA) as the standard of reference. Methods: In 33 centers (in US and Europe) 533 patients, eligible for CXA or SPECT, were enrolled in this multivendor trial. SPECT and CXA were performed within 4 weeks before or after CMR in all patients. Prevalence of CAD in the sample was 49% and 515 patients received MR contrast medium. Drop-out rates for CMR and SPECT were 5.6% and 3.7%, respectively (ns). The study was powered for the primary endpoint of non-inferiority of CMR vs SPECT for both, sensitivity and specificity for the detection of CAD (using a single-threshold reading), the results for the primary endpoint were reported elsewhere. In this article secondary endpoints are presented, i.e. the diagnostic performance of CMR versus SPECT in subpopulations such as multi-vessel disease (MVD), in men, in women, and in patients without prior myocardial infarction (MI). For diagnostic performance assessment the area under the receiver-operator-characteristics-curve (AUC) was calculated. Readers were blinded versus clinical data, CXA, and imaging results. Results: The diagnostic performance (= area under ROC = AUC) of CMR was superior to SPECT (p = 0.0004, n = 425) and to gated-SPECT (p = 0.018, n = 253). CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1-3 vessel disease and p = 0.015, n = 140 in MVD). Conclusion: In this large multicenter, multivendor study the diagnostic performance of perfusion-CMR to detect CAD was superior to perfusion SPECT in the entire population and in sub-groups. Perfusion-CMR can be recommended as an alternative for SPECT imaging. KW - coronary disease KW - perfusion KW - contrast KW - ischemia KW - women KW - emission-computed-tomography KW - noninvasive detection KW - intervention KW - randomized-trial KW - cardiovascular magnetic resonance KW - stress perfusion KW - prognostic value KW - angiography KW - scintigraphy Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-134256 VL - 14 IS - 61 ER - TY - JOUR A1 - Lv, Xiaoqun A1 - Zhang, Lingyun A1 - Zhu, Yanyan A1 - Said, Harun M. A1 - Shi, Jimin A1 - Xu, Guoxiong T1 - Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer JF - Journal of Cancer N2 - Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC. KW - nicotinamide phosphoribosyltransferase KW - signaling pathways KW - gastric cancer KW - overexpression KW - cell proliferation KW - tumor biomarker KW - adenocarcinoma KW - Nampt KW - visfatin KW - PBEF KW - breast cancer KW - prognostic value KW - visfatin levels KW - inhibitor KW - expression KW - adipocytokines Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144516 VL - 6 IS - 9 ER - TY - JOUR A1 - Wester, Hans Jürgen A1 - Keller, Ulrich A1 - Schottelius, Margret A1 - Beer, Ambros A1 - Philipp-Abbrederis, Kathrin A1 - Hoffmann, Frauke A1 - Šimeček, Jakub A1 - Gerngross, Carlos A1 - Lassmann, Michael A1 - Herrmann, Ken A1 - Pellegata, Natalia A1 - Rudelius, Martina A1 - Kessler, Horst A1 - Schwaiger, Markus T1 - Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging JF - Theranostics N2 - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders. KW - acute myeloid leukemia KW - prognostic value KW - therapeutic target KW - chemokine receptor KW - CXCR4 KW - lymphoma KW - in vivo imaging KW - positron emission tomography Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-144537 VL - 5 IS - 6 ER -